

## Total Synthesis of a Glyoxalase I Inhibitor and Its Precursor, (-)-KD16-U1

Kuniaki Tatsuta\*, Shohei Yasuda, Nobuyuki Araki, Masaaki Takahashi, and Yuko Kamiya


Department of Applied Chemistry, School of Science and Engineering, Waseda University  
3-4-1 Ohkubo, Shinjuku, Tokyo 169, Japan

Received 7 October 1997; accepted 31 October 1997

**Abstract:** A glyoxalase I inhibitor and (-)-KD16-U1 have been synthesized from D-ribonic acid  $\gamma$ -lactone through  $\text{SnCl}_4$ -promoted cyclization of a phenylsulfonyl enol silyl ether and regioselective introduction of a hydroxymethyl group. © 1997 Elsevier Science Ltd. All rights reserved.

A glyoxalase I inhibitor (**9**) was isolated in 1975 from the culture broth of *Streptomyces griseosporus* by Umezawa and co-workers.<sup>1)</sup> The absolute structure was determined by chemical studies and X-ray analysis.<sup>2)</sup> Its precursor, (-)-KD16-U1 (**8**), had been already isolated in 1974 from the culture broth of *Streptomyces filipinensis* by a chemical screening method developed in our laboratories,<sup>3)</sup> and converted to the aforementioned glyoxalase I inhibitor by treatment with crotonic acid and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ .<sup>4)</sup> The glyoxalase system, which consists of glyoxalase I, glyoxalase II and reduced glutathione, catalyzes the conversion of  $\alpha$ -keto aldehydes to  $\alpha$ -hydroxy acids.<sup>1)</sup> The glyoxalase I inhibitor (**9**) has also been reported to exhibit antitumor activities.<sup>1)</sup> The structures and bioactivities of these compounds **8** and **9** have attracted our attention because of our program in developing novel methodology for the preparation of densely-functionalized carbocycles from carbohydrates.<sup>5,6)</sup> The first synthesis was achieved by Vasella's group in which methyl  $\alpha$ -D-glucopyranoside was effectively used as a starting material.<sup>7)</sup> Recently, the  $\text{SnCl}_4$ -promoted aldol-like cyclization of phenylsulfonyl enol silyl ethers containing a dimethyl acetal has been explored extensively in our laboratories.<sup>6)</sup> This transformation is ideally suited to the synthesis of carbocycle-containing natural products and carbohydrates, since the core skeleton arises after appropriate replacement of the phenylsulfonyl group. As an illustration of these strategies, we recently disclosed the total synthesis of (-)-PF1092s.<sup>5)</sup> Herein, we describe the novel synthesis of (-)-glyoxalase I inhibitor (**9**) and its precursor, (-)-KD16-U1 (**8**).

In our retrosynthetic analysis, it was proposed that (-)-KD16-U1 (**8**) could be obtained from the



corresponding  $\alpha$ -phenylsulfonyl cyclohexenone **6** through the Michael type addition of tributylstannyl-lithium followed by trapping with formaldehyde and desulfonylation.<sup>8)</sup> The cyclohexenone **6** would arise from the enol silyl ether containing the dimethyl acetal **5**, which originates from one-step opening of the phenylsulfonylmethyl furanose **4**. Thus, the starting material simplifies to commercially available D-ribonic acid  $\gamma$ -lactone.

In practice, the *O*-trityl derivative **19**<sup>9)</sup> was silylated, followed by reductive de-*O*-tritylation to give the alcohol **2** (mp 116°C,  $[\alpha]_D +46^\circ$ )<sup>10)</sup>. Pfitzner-Moffatt oxidation and acetal formation gave **3** (mp 93°C,  $[\alpha]_D +14^\circ$ ). Reaction of **3** with lithiated methyl phenyl sulfone afforded the furanose **4** (mp 136°C,  $[\alpha]_D +22^\circ$ ). This was silylated to produce, as expected,<sup>5)</sup> the labile enol silyl ether **5** having a simultaneously silylated hydroxy group (mp 108°C,  $[\alpha]_D +37^\circ$ ). The SnCl<sub>4</sub>-promoted cyclization of **5** resulted in the formation of the cyclohexenone **6** (mp 197°C,  $[\alpha]_D -120^\circ$ ). Addition of tributylstannyl-lithium<sup>8)</sup> to **6** was followed by trapping of the intermediary  $\beta$ -tributylstannyl sulfone with formaldehyde. This reaction gave an adduct which, upon treatment with silica gel, was converted through  $\beta$ -elimination of the tributylstannyl group to the desired  $\alpha$ -hydroxymethyl-cyclohexenone **7** (oil,  $[\alpha]_D -72^\circ$ ). De-*O*-silylation with 90% TFA afforded **8** [mp 114°C,  $[\alpha]_D -166^\circ(\text{H}_2\text{O})$ ], which was identical with the natural (-)-KD16-U1 (**8**) in all respects.<sup>3)</sup>

The synthetic (-)-KD16-U1 (**8**) was treated with crotonic acid and BF<sub>3</sub>·Et<sub>2</sub>O, as previously reported in our laboratories,<sup>4)</sup> to give the selectively acylated product **9** [mp 181°C,  $[\alpha]_D -111^\circ(\text{MeOH})$ ] identical with the natural glyoxalase I inhibitor (**9**).<sup>1)</sup>

Adaptation of this synthetic strategy for the construction of other cyclohexenones is under investigation.

**Acknowledgment:** We are grateful to Advanced Research Institute for Science and Engineering, Waseda University, and High-Tech Research Center Project the Ministry of Education, Science, Sports and Culture for the generous support of our program.

## REFERENCES AND NOTES

1. Takeuchi, T.; Chimura, H.; Hamada, M.; Umezawa, H.; Yoshika, O.; Oguchi, N.; Takahashi, Y.; Matsuda, A. *J. Antibiot.*, **28**, 737-742 (1975).
2. Chimura, H.; Nakamura, H.; Takita, T.; Takeuchi, T.; Umezawa, H.; Kato, K.; Saito, S.; Tomisawa, H.; Iitaka, Y. *J. Antibiot.*, **28**, 743-748 (1975).
3. Tatsuta, K.; Tsuchiya, T.; Mikami, N.; Umezawa, S.; Umezawa, H.; Naganawa, H. *J. Antibiot.*, **27**, 579-586 (1974).
4. Umezawa, S.; Takita, K.; Takeuchi, T.; Umezawa, H.; Takita, T. *Chem. Abstr.*, **87**, 184080b (1977).
5. Tatsuta, K.; Niwata, Y.; Umezawa, K.; Tushima, K.; Nakata, M. *Tetrahedron Lett.*, **31**, 1171-1172 (1990); *Carbohydr. Res.*, **222**, 189-203 (1991).
6. Tatsuta, K.; Yasuda, S.; Kurihara, K.; Tanabe, K.; Shinei, R.; Okonogi, T. *Tetrahedron Lett.*, **38**, 1439-1442 (1997).
7. Mirza, S.; Molleyres, L.-P.; Vasella, A. *Helv. Chim. Acta*, **68**, 988-996 (1985).
8. Ochiai, M.; Ukita, T.; Fujita, E. *J. Chem. Soc. Chem. Commun.*, **1983**, 619-621 (1983).
9. Ireland, R. E.; Anderson, R. C.; Badoud, R.; Fitzsimmons, B. J.; McGarvey, G. J.; Thaisrivongs, S.; Wilcox, C. S. *J. Am. Chem. Soc.*, **105**, 1988-2006 (1983).
10. Optical rotations were measured in CHCl<sub>3</sub> using a 0.5 dm tube at 22°C, unless otherwise noted.

Significant <sup>1</sup>H-NMR spectral data (in CDCl<sub>3</sub>; 270, 400 and 500 MHz,  $\delta$ ; TMS=0, unless otherwise noted) are the following. **2**: 1.90(1H, t,  $J=5.6\text{Hz}$ ), 3.51(1H, ABq,  $J=3.0, 4.5, 5.6\text{Hz}$ ), 3.96(1H, ABq,  $J=3.0, 4.0, 5.6\text{Hz}$ ), 4.45(1H, dd,  $J=3.0, 4.5\text{Hz}$ ), **3**: 3.47(3H, s), 3.50(3H, s), 4.23(1H, d,  $J=3.0\text{Hz}$ ), 4.37(1H, d,  $J=3.0\text{Hz}$ ), **4**: 3.46(1H, d,  $J=15.4\text{Hz}$ ), 4.26(1H, d,  $J=15.4\text{Hz}$ ), 7.56(3H, m), 7.98(2H, m), **5**: 3.59(1H, d,  $J=9.0\text{Hz}$ ), 3.79(1H, d,  $J=7.4\text{Hz}$ ), 4.32(1H, d,  $J=9.0\text{Hz}$ ), 4.45(1H, d,  $J=7.4\text{Hz}$ ), 5.77(1H, s), **6**: 4.18(2H, m), 4.74(1H, dd,  $J=2.2, 2.0\text{Hz}$ ), 7.70(1H, dd,  $J=2.2, 1.6\text{Hz}$ ), **7**: 2.28(1H, br), 4.24(2H, m), 6.46(1H, m), **8** (D<sub>2</sub>O): 4.25(1H, d,  $J=14\text{Hz}$ ), 4.32(1H, d,  $J=14\text{Hz}$ ), 4.47(2H, m), 4.82(1H, m), 6.78(1H, m), **9**(DMSO):  $\delta$  1.86(3H, dd,  $J=6.9, 1.8\text{Hz}$ ), 4.17(2H, m), 4.55(1H, m), 4.63(1H, dt,  $J=13.5, 1.5\text{Hz}$ ), 4.75(1H, dt,  $J=13.5, 1.5\text{Hz}$ ), 5.07(1H, d,  $J=3.3\text{Hz}$ ), 5.19(1H, d,  $J=5.5\text{Hz}$ ), 5.37(1H, d,  $J=7.0\text{Hz}$ ), 5.92(1H, dq,  $J=15.6, 1.8\text{Hz}$ ), 6.62(1H, m), 6.93(1H, dq,  $J=15.6, 6.9\text{Hz}$ ).